BioSpace News Archive

RadNet, Inc. announced that it will host a conference call to discuss its second quarter 2022 financial results on Tuesday, August 9th, 2022 at 7:30 a.m. Pacific Time.

BIOLASE, Inc., the global leader in dental lasers, announced that the company has received five new United States patents and seven new foreign patents in the last 12 months.

Ginkgo to acquire Bayer’s 175,000-square-foot Biologics R&D center and enter into a new multi-year platform collaboration with Bayer to advance several agricultural biological programs.

Analysis of nearly 23 million lab tests finds only 1 in 3 patients with latent tuberculosis were also tested for chronic hepatitis B, despite similar risk factors in patients.

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2022 operating and financial results after the market close on August 2nd , 2022.

HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Paul Thibodeau , Ph.D., as Chief Business Officer.

Acquisition is expected to accelerate the development of Ginkgo’s innovative horizontal synthetic biology platform Expect integration of Zymergen’s complementary automation, software, and data science tools.

Cytovale ® , a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, will reveal its 510(k) pending Cytovale system and 10-minute IntelliSep ® sepsis risk stratification test at the American Association for Clinical Chemistry (AACC) annual meeting.

Veru Inc. announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency considers that the currently available safety and efficacy data will support an expedited review of the marketing authorization application for the Company’s sabizabulin treatment in hospitalized COVID-19 patients at high risk for Acute Respiratory Distress Syndrome when the application is submitted.

Navidea Biopharmaceuticals, Inc. today announced the publication of a manuscript titled “Increased Macrophage Specific Arterial Inflammation Relates Uniquely to Non-calcified Plaque and Specific Immune Activation Pathways in People with HIV.